Stanford University - September 2004
Health Discovery Corporation entered into an agreement with Dr. Thomas Stamey of Stanford University Medical Center to analyze what is thought by Dr. Stamey to be the most comprehensive prostate cancer gene chip data base in the world. This data base consists of Affymetrix gene chips containing 25,000 prostate related genes. This data is from 92 patient representing 9 classes of prostate disease - from BPH through all grades of prostate cancer. Using this data base, we hope to identify new biomarkers for prostate cancer. We will also use our patent protected computational techniques such as Support Vector Machine and FractalGenomics Modeling to analyze this data to determine the most relevant proteins to be used for diagnostics and drug targets. All discoveries will be jointly
owned by us and Dr. Stamey with us having a world-wide exclusive license for commercialization.
Stanford University - March 2004
Health Discovery Corporation signed an agreement with Stanford University to use Health Discovery Corporations proprietary and patent protected Fractal Genomics Modeling techniques to identify new patterns of biomarkers in lymphatic insufficiency and its response to therapeutic lymphangiogenesis. According to the agreement, ownership of Research Program Inventions conceived, discovered or reduced to practice under the Research Program will be determined based on inventorship. As such, any invention discovered using our analytical tools on this Stanford database will be jointly owned by Health Discovery Corporation and Stanford University.
The University of Miami - March 2004
Health Discovery Corporation announced the signing of an Agreement with The University of Miami to use Health Discovery Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new patterns of biomarkers in AIDS Related Dementia. It is hoped that this newly discovered information will allow physicians to better understand the pathogenesis of AIDS Related Dementia and will assist in the diagnosis and treatment of this devastating disease.
Under the terms of the Agreement, The University of Miami has granted Health Discovery Corporation joint ownership on any product, invention, discovery or new use arising out of or developed by Health Discovery Corporation utilizing its unique computational methods.
M.D. Anderson Cancer Center - January 2004
Health Discovery Corporation signed its second Biomarker and Pathway Discovery Agreement with The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. Under the terms of the agreement, The University of Texas, M.D. Anderson Cancer Center, has granted the Company a first option to obtain an exclusive worldwide royalty-bearing commercial license to commercialize any discovered prostate cancer biomarkers or pathways identified by the Company utilizing its proprietary and patent protected Fractal Genomics Modeling Techniques.
Dr. Herbert Fritsche, Professor and Chief of Clinical Chemistry, at M.D. Anderson Cancer Center said, "This second collaboration with Health Discovery Corporation will give us access to a new systems biology approach for data analysis that will lead to new biomarker and pathway discovery in prostate cancer. We hope to use the findings of this study to develop new diagnostic approaches for prostate cancer and improve the clinical management of these patients."
M.D. Anderson Cancer Center - October 2003
Health Discovery Corporation signed a Biomarker and Pathway Discovery Agreement with The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. Under the terms of the agreement, The University of Texas, M.D. Anderson Cancer Center, has granted the Company a first option to obtain an exclusive worldwide royalty-bearing commercial license to commercialize any discovered leukemia biomarkers or pathways identified by the Company utilizing its proprietary and patent protected Fractal Genomics Modeling Techniques.